Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1 - 20. (canceled)

21. (currently amended) A method for the therapeutic therapy of colorectal cancer, ~~prostate cancer~~, small cell lung cancer, non-small cell lung cancer, breast cancer, ~~pancreatic cancer,~~ renal cancer, or gastric cancer, ~~bladder cancer or ovarian cancer~~ comprising administering to a patient suffering therefrom a pharmaceutically effective amount of a compound of formula I



(I)

or a pharmaceutically acceptable salt or prodrug thereof:

wherein Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally

substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

22 - 27. (canceled)